InvestSMART

Island Pharmaceuticals Limited (ASX:ILA)

ALERT: Price-sensitive ASX Announcement for ILA
Current share price for ILA : $0.450 0.075 (20%)+
Announcement
Release
27 Apr 2026 9:46AM
Price at Release
$0.375
Full Release
download
Summary
Island Pharmaceuticals Limited, an Australian antiviral drug development company, has made significant progress in the clinical development of its antiviral drug, Galidesivir, during the quarter ending 31 March 2026. The company received strategic regulatory guidance from the US FDA, aligning on the Animal Rule pathway, which de-risks the development process and supports potential approval and U.S. government procurement. Island also executed a Cooperative Research and Development Agreement (CRADA) with the US Army's USAMRIID and The Geneva Foundation to advance Galidesivir's development. Financially, the company secured $9 million in strategic funding to strengthen its balance sheet and received an R&D Tax Incentive Refund under the Australian government's scheme. The company aims to advance Galidesivir through the FDA pathway and position itself within U.S. biodefense procurement and non-dilutive revenue opportunities.
Key Points
  • Island Pharmaceuticals advanced Galidesivir's clinical development with the FDA's alignment on the Animal Rule pathway.
  • CRADA executed with USAMRIID and The Geneva Foundation to further Galidesivir's development.
  • Secured $9 million in strategic funding and received an R&D Tax Incentive Refund.
  • The company is focused on biodefense procurement and non-dilutive revenue opportunities.
  • Galidesivir's development validated by the FDA, highlighting potential for government procurement.
  • Galidesivir is part of a dual development strategy alongside ISLA-101.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.